TY - JOUR
T1 - Lipoprotein(a) and Coronary Plaque in Asymptomatic Individuals
T2 - The Miami Heart Study at Baptist Health South Florida
AU - Mszar, Reed
AU - Cainzos-Achirica, Miguel
AU - Valero-Elizondo, Javier
AU - Lahan, Shubham
AU - Al-Kindi, Sadeer G.
AU - Quispe, Renato
AU - Ali, Shozab S.
AU - Arias, Lara
AU - Saxena, Anshul
AU - Shah, Svati H.
AU - Cury, Ricardo C.
AU - Budoff, Matthew J.
AU - Blaha, Michael J.
AU - Shapiro, Michael D.
AU - Sharma, Garima
AU - Santos, Raul D.
AU - Blankstein, Ron
AU - Feldman, Theodore
AU - Fialkow, Jonathan
AU - Nasir, Khurram
N1 - Publisher Copyright:
© 2024 American Heart Association, Inc.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - BACKGROUND: Elevated levels of lipoprotein(a) (Lp(a)) are independently associated with an increased risk of atherosclerotic cardiovascular disease events. However, the mechanisms driving this association are poorly understood. We aimed to evaluate the association between Lp(a) and coronary plaque characteristics in a contemporary US cohort without clinical atherosclerotic cardiovascular disease, undergoing coronary computed tomography angiography, the noninvasive gold standard for the assessment of coronary atherosclerosis. METHODS: We used baseline data from the Miami Heart Study—a community-based, prospective cohort study—which included asymptomatic adults aged 40 to 65 years evaluated using coronary computed tomography angiography. Those taking any lipid-lowering therapies were excluded. Elevated Lp(a) was defined as ≥125 nmol/L. Outcomes included any plaque, coronary artery calcium score >0, maximal stenosis ≥50%, presence of any high-risk plaque feature (positive remodeling, spotty calcification, low-attenuation plaque, napkin ring), and the presence of ≥2 high-risk plaque features. RESULTS: Among 1795 participants (median age, 52 years; 54.3% women; 49.6% Hispanic), 291 (16.2%) had Lp(a) ≥125 nmol/L. In unadjusted analyses, individuals with Lp(a) ≥125 nmol/L had a higher prevalence of all outcomes compared with Lp(a) <125 nmol/L, although differences were only statistically significant for the presence of any coronary plaque and ≥2 high-risk features. In multivariable models, elevated Lp(a) was independently associated with the presence of any coronary plaque (odds ratio, 1.40, [95% CI, 1.05–1.86]) and with ≥2 high-risk features (odds ratio, 3.94, [95% CI, 1.82–8.52]), although only 35 participants had this finding. Among participants with a coronary artery calcium score of 0 (n=1200), those with Lp(a) ≥125 nmol/L had a significantly higher percentage of any plaque compared with those with Lp(a) <125 nmol/L (24.2% versus 14.2%; P<0.001). CONCLUSIONS: In this contemporary analysis, elevated Lp(a) was independently associated with the presence of coronary plaque. Larger studies are needed to confirm the strong association observed with the presence of multiple high-risk coronary plaque features.
AB - BACKGROUND: Elevated levels of lipoprotein(a) (Lp(a)) are independently associated with an increased risk of atherosclerotic cardiovascular disease events. However, the mechanisms driving this association are poorly understood. We aimed to evaluate the association between Lp(a) and coronary plaque characteristics in a contemporary US cohort without clinical atherosclerotic cardiovascular disease, undergoing coronary computed tomography angiography, the noninvasive gold standard for the assessment of coronary atherosclerosis. METHODS: We used baseline data from the Miami Heart Study—a community-based, prospective cohort study—which included asymptomatic adults aged 40 to 65 years evaluated using coronary computed tomography angiography. Those taking any lipid-lowering therapies were excluded. Elevated Lp(a) was defined as ≥125 nmol/L. Outcomes included any plaque, coronary artery calcium score >0, maximal stenosis ≥50%, presence of any high-risk plaque feature (positive remodeling, spotty calcification, low-attenuation plaque, napkin ring), and the presence of ≥2 high-risk plaque features. RESULTS: Among 1795 participants (median age, 52 years; 54.3% women; 49.6% Hispanic), 291 (16.2%) had Lp(a) ≥125 nmol/L. In unadjusted analyses, individuals with Lp(a) ≥125 nmol/L had a higher prevalence of all outcomes compared with Lp(a) <125 nmol/L, although differences were only statistically significant for the presence of any coronary plaque and ≥2 high-risk features. In multivariable models, elevated Lp(a) was independently associated with the presence of any coronary plaque (odds ratio, 1.40, [95% CI, 1.05–1.86]) and with ≥2 high-risk features (odds ratio, 3.94, [95% CI, 1.82–8.52]), although only 35 participants had this finding. Among participants with a coronary artery calcium score of 0 (n=1200), those with Lp(a) ≥125 nmol/L had a significantly higher percentage of any plaque compared with those with Lp(a) <125 nmol/L (24.2% versus 14.2%; P<0.001). CONCLUSIONS: In this contemporary analysis, elevated Lp(a) was independently associated with the presence of coronary plaque. Larger studies are needed to confirm the strong association observed with the presence of multiple high-risk coronary plaque features.
KW - atherosclerosis
KW - calcium
KW - cardiovascular diseases
KW - lipoprotein(a)
KW - primary prevention
UR - http://www.scopus.com/inward/record.url?scp=85198932912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198932912&partnerID=8YFLogxK
U2 - 10.1161/CIRCIMAGING.123.016152
DO - 10.1161/CIRCIMAGING.123.016152
M3 - Article
C2 - 39012945
AN - SCOPUS:85198932912
SN - 1941-9651
VL - 17
SP - 548
EP - 560
JO - Circulation: Cardiovascular Imaging
JF - Circulation: Cardiovascular Imaging
IS - 7
ER -